Every material Form 8-K Omada Health, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Omada Health reported third quarter 2026 results, with revenue of $91 million, up from $68 million a year earlier, and net income of $7 million compared with a net loss of $3 million in Q3 2025. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, which should matter to shareholders because both headline measures moved up from the prior outlook.
Q3 2026 revenue of $91 million, up 34% from $68 million in Q3 2025
Net income of $7 million, compared with a net loss of $3 million in Q3 2025
Full-year 2026 revenue guidance raised to $344 million to $346 million from $334 million to $340 million
Full-year 2026 adjusted EBITDA guidance raised to $32 million to $34 million from $21 million to $27 million
Omada Health reported second-quarter 2026 revenue of $88 million, up from $61 million a year earlier, and net income of $5 million versus a net loss of $5 million in Q2 2025. The company raised its full-year 2026 revenue and adjusted EBITDA ranges and said co-founder Sean Duffy will move to Executive Chair while President Wei-Li Shao becomes CEO on January 1, 2027.
Q2 2026 revenue of $88 million, up 43% from $61 million in Q2 2025; gross margin of 73% versus 66%
Net income of $5 million in Q2 2026 compared with a net loss of $5 million in Q2 2025; adjusted EBITDA of $11 million
2026 revenue outlook raised to $334 million to $340 million from $322 million to $330 million; adjusted EBITDA outlook raised to $21 million to $27 million from $14 million to $20 million
Wei-Li Shao to succeed Sean Duffy as CEO effective January 1, 2027; Jeryl Hilleman to become Lead Independent Director
Omada Health reported first quarter 2026 revenue of $78 million, up 42% from a year earlier, and a net loss of $3 million, narrower than the $9 million loss in Q1 2025. The company raised its full-year 2026 revenue outlook to $322 million to $330 million, from $312 million to $322 million, and its adjusted EBITDA outlook to $14 million to $20 million, from $7 million to $15 million.
Q1 2026 revenue of $78 million, up 42% year over year; total members reached 1.02 million, up 51%
Net loss of $3 million in Q1 2026, compared with $9 million in Q1 2025; adjusted EBITDA of $1 million, compared with a $4 million loss
2026 revenue outlook raised to $322 million to $330 million; adjusted EBITDA outlook raised to $14 million to $20 million
Free cash flow was negative $13.4 million in Q1 2026, compared with negative $17.4 million in Q1 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Omada Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →